2.96
-0.2(-6.33%)
Currency In USD
| Previous Close | 3.16 |
| Open | 3.16 |
| Day High | 3.25 |
| Day Low | 2.93 |
| 52-Week High | 3.95 |
| 52-Week Low | 1.01 |
| Volume | 1.2M |
| Average Volume | 1.31M |
| Market Cap | 213.86M |
| PE | -1.42 |
| EPS | -2.08 |
| Moving Average 50 Days | 1.67 |
| Moving Average 200 Days | 1.5 |
| Change | -0.2 |
If you invested $1000 in Zentalis Pharmaceuticals, Inc. (ZNTL) since IPO date, it would be worth $127.59 as of January 18, 2026 at a share price of $2.96. Whereas If you bought $1000 worth of Zentalis Pharmaceuticals, Inc. (ZNTL) shares 5 years ago, it would be worth $60.15 as of January 18, 2026 at a share price of $2.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial pl
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertibSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
GlobeNewswire Inc.
Aug 26, 2025 8:05 PM GMT
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertiseSAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-